Search
Descriptor English: Ranibizumab
Descriptor Spanish: Ranibizumab
Descriptor ranibizumab
Scope note: Un fragmento monoclonal recombinante humanizado anticuerpo que se une VEGF-A para evitar su unión a VEGFR-1 y VEGFR-2. Esta actividad reduce permeabilidad de los vasos y la angiogénesis en el tratamiento de la DEGENERACIÓN MACULAR neovascular relacionada con la edad.
Descriptor Portuguese: Ranibizumab
Descriptor French: Ranibizumab
Entry term(s): Lucentis
RhuFab V2
V2, RhuFab
Tree number(s): D12.776.124.486.485.114.224.060.868
D12.776.124.790.651.114.224.060.868
D12.776.377.715.548.114.224.200.868
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000069579
Scope note: A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Angiogenesis Inhibitors
Registry Number: ZL1R02VT79
Public MeSH Note: 2016; RANIBIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2005-2011
History Note: 2016 (2005)
Related: Vascular Endothelial Growth Factor A MeSH
DeCS ID: 55979
Unique ID: D000069579
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2016/01/01
Date of Entry: 2015/07/01
Revision Date: 2017/04/10
Ranibizumab - Preferred
Concept UI M0481787
Scope note A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
Preferred term Ranibizumab
Entry term(s) RhuFab V2
V2, RhuFab
Lucentis - Narrower
Concept UI M0499546
Preferred term Lucentis



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey